Group 1 - The core point of the news is that TEBIO has experienced a continuous decline in stock price, dropping 2.14% on January 14, with a total market value of 30.59 billion yuan and a cumulative decline of 11.1% over five days [1] - TEBIO specializes in the research, production, and sales of recombinant proteins and long-acting modified drugs, with its main business revenue composition being 86.85% from antiviral drugs, 12.87% from blood/tumor drugs, and 0.27% from other supplementary products [1] Group 2 - From the perspective of TEBIO's top ten circulating shareholders, E Fund's ETF has reduced its holdings by 856,700 shares, now holding 5.881 million shares, which is 1.45% of the circulating shares, resulting in a floating loss of approximately 9.64 million yuan today [2] - The E Fund's ETF has a total scale of 76.76 billion yuan, with a year-to-date return of 9.33% and a one-year return of 55.09% [2] - The fund managers, Lin Weibin and Cheng Xi, have significant experience, with Lin managing assets totaling 122.69 billion yuan and achieving a best return of 80.47% during his tenure [2]

Group 1 - The core transaction of Te Bao Bio occurred on January 13, with a volume of 99,000 shares and a transaction amount of 7.5814 million yuan, at a price of 76.58 yuan per share [2][4] - In the last three months, Te Bao Bio has recorded a total of 7 block trades, amounting to 54.2789 million yuan [3] - The closing price of Te Bao Bio on the day of the transaction was 76.58 yuan, reflecting a decrease of 0.49%, with a daily turnover rate of 0.59% and a total trading volume of 186 million yuan [3] Group 2 - The latest margin financing balance for Te Bao Bio is 1.382 billion yuan, which has increased by 16.7976 million yuan over the past five days, representing a growth of 1.23% [4] - The net outflow of main funds for Te Bao Bio on the transaction day was 6.3594 million yuan, while the total net inflow over the past five days was 14.7998 million yuan [3]

Core Viewpoint - On January 13, 14 stocks from the STAR Market experienced block trading, with a total transaction amount of 315 million yuan and a cumulative trading volume of 9.96 million shares [1]. Group 1: Trading Overview - A total of 38 block trades were recorded for the 14 STAR Market stocks, with the highest transaction amount attributed to Hu Silicon Industry, which had a trading volume of 6.61 million shares and a transaction amount of 149 million yuan [1]. - Other notable transactions included Huaxi Biological and Mingwei Electronics, with transaction amounts of 58.29 million yuan and 26.62 million yuan, respectively [1]. - The average price of block trades for the stocks showed significant variations, with some stocks trading at discounts to their closing prices, such as Zhongkong Technology at a discount rate of 27.20% [1][4]. Group 2: Price Performance - The STAR 50 Index fell by 2.80% on the same day, with 167 stocks, or 27.83%, experiencing price increases [1]. - Among the stocks involved in block trading, the average price change was a decrease of 0.10%, with notable gainers including Zhuoyi Information, Zhongkong Technology, and Huaxi Biological, which saw increases of 13.13%, 9.90%, and 2.25%, respectively [1]. - Conversely, stocks like Bolite, Mingwei Electronics, and Hu Silicon Industry faced declines of 11.41%, 4.87%, and 3.27% [1]. Group 3: Institutional Participation - Out of the block trades, 13 transactions involved institutional buyers or sellers, focusing on three stocks, with Huaxi Biological leading in institutional buy amounts at 22.17 million yuan [2]. - Other significant institutional purchases included Tiannai Technology and Yunlu Co., with buy amounts of 7.09 million yuan and 2.01 million yuan, respectively [2]. - In terms of capital flow, four stocks saw net inflows, with Huaxi Biological, Yunlu Co., and Lante Optical leading in net inflow amounts of 67.52 million yuan, 14.59 million yuan, and 10.73 million yuan, respectively [2].

Group 1 - The core transaction involved 99,000 shares of TEBIO, with a total transaction value of 7.5814 million yuan, accounting for 3.93% of the total trading volume on that day [1] - The transaction price was 76.58 yuan, which remained unchanged compared to the market closing price of 76.58 yuan [1] - The buying brokerage involved in the transaction was Guotai Junan, indicating institutional interest in TEBIO [2]

Group 1 - The core point of the news is that TEBIO has experienced a decline in stock price, falling 0.49% to 76.58 CNY per share, with a total market capitalization of 31.259 billion CNY and a cumulative drop of 9.16% over the last four days [1] - TEBIO, established on August 7, 1996, is located in Xiamen, Fujian Province, and specializes in the research, production, and sales of recombinant proteins and long-acting modified drugs, with 86.85% of its revenue coming from antiviral drugs, 12.87% from blood/cancer drugs, and 0.27% from other sources [1] Group 2 - From the perspective of fund holdings, Huashang Fund has a significant position in TEBIO, with its Huashang Innovation Medical Mixed A fund holding 26,700 shares, unchanged from the previous period, representing 4.31% of the fund's net value [2] - The Huashang Innovation Medical Mixed A fund, established on June 13, 2023, has a current size of 31.7429 million CNY, with a year-to-date return of 25.18% and a one-year return of 23.02%, ranking 3412 out of 8179 and 3511 out of 8148 respectively [2]

1月13日，特宝生物跌0.49%，截至发稿，报76.58元/股，成交1.86亿元，换手率0.59%，总市值312.59亿 元。特宝生物股价已经连续4天下跌，区间累计跌幅9.16%。 成曦累计任职时间9年254天，现任基金资产总规模2501.21亿元，任职期间最佳基金回报131.04%， 任 职期间最差基金回报-67.89%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 责任编辑：小浪快报 易方达上证科创板50ETF（588080）成立日期2020年9月28日，最新规模767.61亿。今年以来收益 12.47%，同类排名587/5517；近一年收益59.83%，同类排名1063/4203；成立以来收益9.04%。 易方达上证科创板50ETF（588080）基金经理为林伟斌、成曦。 截至发稿，林伟斌累计任职时间12年317天，现任基金资产总规模1226.92亿元，任职期间最佳基金回报 80.47%， 任职期间最差基金回报-22.14%。 资料显示，厦门特宝生物工程股份有限 ...

Group 1 - The A-share market experienced fluctuations with the Shanghai Composite Index showing volatility, while trading volume exceeded 1.8 trillion yuan, indicating sustained active trading [1] - The innovative drug sector saw significant strength, with the Science and Technology Innovation Drug ETF Huatai (589120) surging over 3% as funds continued to flow into it for two consecutive days, driven by optimism around "BD going global + AI healthcare + brain-computer interfaces" [1] - The top ten constituent stocks of the Huatai ETF include companies like BeiGene (688235) and Junshi Biosciences (688180), with Rongchang Biopharmaceuticals (688331) leading with a 17.29% increase [1][5] Group 2 - Rongchang Biopharmaceuticals announced a licensing agreement with AbbVie for RC148, which includes a $650 million upfront payment and potential milestone payments up to $4.95 billion, along with double-digit royalties on net sales outside Greater China [1][2] - The transaction size of the upfront payment ranks among the top ten for domestic innovative drug companies going global, indicating the potential of RC148 in the global market [2] - The trend in the industry is shifting from "early licensing" to "deep binding" partnerships, with companies like Hengrui Medicine and Qianxin Biopharmaceuticals actively engaging in new cooperative models that share risks and long-term benefits [4][6] Group 3 - The innovative drug sector is expected to enter a phase of significant growth, with a focus on the lifecycle of BD transactions, which includes achieving overseas clinical validation and profit-sharing from sales [3][4] - The market anticipates a busy period for BD transactions, with 49 deals totaling over $39 billion since October, as multinational corporations continue to expand in China [6] - The upcoming JPM conference in January 2026 is expected to catalyze further activity in the sector, coinciding with the annual report cycle, suggesting a peak in data disclosures and BD transactions [6]

Core Viewpoint - The new basic medical insurance drug catalog and commercial insurance innovative drug catalog have been officially implemented as of January 1, 2026, significantly benefiting families of children with growth hormone deficiencies through the inclusion of the long-acting growth hormone Yipeisheng in the insurance coverage, which has seen a price reduction of over 50% [1] Group 1 - The long-acting growth hormone Yipeisheng, developed by Tebao Biopharmaceuticals, is now included in the medical insurance payment scope [1] - The price reduction of over 50% for Yipeisheng, combined with the medical insurance reimbursement policy, will greatly alleviate the financial burden on families of affected children [1] - Yipeisheng has completed the online listing process in all 31 provinces (regions, municipalities) across the country, with new policies being implemented to ensure timely access to the benefits for families [1]

Core Viewpoint - In 2025, the Chinese stock market showed remarkable performance, with the Shanghai Composite Index increasing by 18.4% year-on-year, reaching 3968.84 points by December 31, 2025 [1] Group 1: Performance of Xiamen Listed Companies - In 2025, 70 listed companies in Xiamen performed well, with 42 companies outperforming the market [1] - 15 listed companies in Xiamen reached historical highs in stock prices, reflecting strong operational fundamentals and growth potential [2] - The total market capitalization of the 70 listed companies in Xiamen was 9030.35 billion, a 44.1% increase compared to the previous year [2] - 30 companies had a market capitalization exceeding 100 billion, accounting for over 40% of the total, with Xiamen Tungsten leading at 651.86 billion [2] - 56 companies saw an increase in market capitalization, with 13 companies experiencing growth exceeding 100% [2] Group 2: New Listings and Recognition - In 2025, Xiamen added 6 new listed companies, the highest in nearly four years, including 2 A-share companies [5] - Among the 70 listed companies, 26 were recognized as national "specialized and innovative" small giant enterprises, and over 80% were high-tech enterprises [6] - Several Xiamen listed companies received honors, including Xiamen Tungsten and Jibite, recognized for best practices in corporate governance [7][9] - The number of listed companies in Xiamen has surpassed 100, with 70 being domestic listed companies, representing about 40% of the provincial total [10]

Group 1 - The core point of the news is that TeBao Bio experienced a 5.2% decline in stock price, reaching 76.40 yuan per share, with a trading volume of 251 million yuan and a turnover rate of 0.79%, resulting in a total market capitalization of 31.186 billion yuan [1] - TeBao Bio, established on August 7, 1996, is located in Xiamen, Fujian Province, and was listed on January 17, 2020. The company specializes in the research, production, and sales of recombinant proteins and long-acting modified drugs [1] - The main revenue composition of TeBao Bio includes 86.85% from antiviral drugs, 12.87% from blood/tumor drugs, and 0.27% from other supplementary products [1] Group 2 - From the perspective of fund holdings, HSBC Jintrust Fund has one fund heavily invested in TeBao Bio. The HSBC Jintrust Medical Pioneer Mixed A Fund (012358) reduced its holdings by 63,200 shares in the third quarter, now holding 160,200 shares, which accounts for 3.96% of the fund's net value, ranking as the ninth largest holding [2] - The HSBC Jintrust Medical Pioneer Mixed A Fund (012358) was established on July 12, 2021, with a current size of 170 million yuan. Year-to-date returns are 12.33%, ranking 269 out of 9,012 in its category; the one-year return is 86.56%, ranking 323 out of 8,157; and since inception, it has a loss of 15.62% [2] - The fund manager of HSBC Jintrust Medical Pioneer Mixed A Fund is Li Bokan, who has been in the position for 1 year and 13 days, with total assets under management of 340 million yuan. The best fund return during his tenure is 76.34%, while the worst is 75.58% [2]